Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: StemCells Inc

Market Cap 120M 103M 95.14M 89.06M 167M 11.36B 169M 1.12B 438M 5.53B 449M 439M 19.15B P/E Ratio 2026 *
-5.93x
P/E Ratio 2027 * -5.56x
Enterprise Value 120M 103M 95.14M 89.06M 167M 11.36B 169M 1.12B 438M 5.53B 449M 439M 19.15B EV / Sales 2026 *
34.6x
EV / Sales 2027 * 11.3x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
06-09 Microbot Medical Inc. Announces A Notable Health System as the First in Michigan to Adopt the Liberty Endovascular Robotic System CI
06-02 Microbot Medical Inc. Secures First North Carolina Healthcare System to Adopt the LIBERTY Endovascular Robotic System CI
05-26 Microbot Medical Inc. Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System CI
05-18 Microbot Medical Inc. - Shareholder/Analyst Call
05-14 Microbot Medical recorded revenue during its quarter ended March 31, benefiting from limited market release of Liberty System RE
05-14 Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-05 Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites RE
05-05 Microbot Medical Inc Wins Accounts for Liberty Endovascular Robotic System Across Key Territories CI
04-13 Microbot Medical Inc. Commences Full Market Release Of Liberty Endovascular Robotic System In The U.S CI
03-26 Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-26 Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®?s LIBERTY® Endovascular Robotic System CI
03-24 Microbot Medical Inc. Strengthens Liberty Endovascular Robotic System Position with Publication of Access Pvi Pivotal Study CI
02-24 Tampa General Hospital Is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System CI
Manager TitleAgeSince
Chief Executive Officer 54 02/08/1988
Director of Finance/CFO 47 01/04/2022
Chief Operating Officer - 21/01/2025
Director TitleAgeSince
Director/Board Member 61 28/11/2016
Director/Board Member 68 12/12/2017
Director/Board Member 52 01/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.78%+1.45%+57.60%+89.18% 23.61B
Weighted average by Cap. +1.05%+1.48%+57.30%+96.08%

Financials

2026 *2027 *
Net sales 3.45M 2.98M 2.75M 2.57M 4.82M 328M 4.89M 32.42M 12.64M 160M 12.95M 12.67M 553M 10.6M 9.16M 8.44M 7.9M 14.8M 1.01B 15.03M 99.62M 38.84M 490M 39.78M 38.93M 1.7B
Net income -20.45M -17.66M -16.28M -15.24M -28.55M -1.94B -28.99M -192M -74.93M -946M -76.75M -75.11M -3.28B -21.45M -18.53M -17.07M -15.98M -29.95M -2.04B -30.41M -202M -78.59M -992M -80.5M -78.79M -3.44B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!